# Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

> **NCT01181258** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 16 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Rituximab
- **BIOLOGICAL:** Interleukin-2
- **BIOLOGICAL:** Natural killer cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Methylprednisolone
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT01181258
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2015-09
- **Final completion:** 2016-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01181258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01181258, "Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01181258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*